Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis

Dipeptidyl peptidase-4 inhibitors (DPP-4i) are emerging glucose-lowering agents through interacting with DPP-4 substrate, impact of which on systemic inflammation in type 2 diabetes mellitus (T2DM) remains unk...
Source: Lipids in Health and Disease - Category: Lipidology Authors: Tags: Research Source Type: research

Related Links:

Authors: Gupta P, Gupta R, Gupta AK Abstract The chronic complications of Diabetes Mellitus (DM), which may be present in as many as 50% of the patients at the time of diagnosis, are a major burden for both individuals with the disease and health systems and it has been estimated that as much as 60-70% of healthcare expenditure related to diabetes (about 670 billion dollars a year) is currently attributable to chronic complications of the disease. These high prevalence rates are widely acknowledged to further rise as poor lifestyle choices and their consequences continue to rise. Adding to that is an aging populati...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
ConclusionThere is a need to increase the awareness of MS among the PHC Physicians. More training programs need to be planned. A better awareness among primary care physician is warranted for an early diagnosis and effective management of MS in Saudi Arabia.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Introduction: To analyze the relationship between adherence to the Mediterranean diet, glucose control, body weight and major cardiovascular (CV) risk factors in people with type 2 diabetes mellitus (T2DM) and to evaluate the impact thereon of specific foods, typical of this dietary pattern.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research
Introduction: To date, the Mediterranean diet is the first therapeutic approach for patients with type 2 diabetes mellitus (T2DM). Conversation Maps ™ (C-Maps™) are interactive educational tools on diabetes, with a strong visual impact. The “Healthy Eating and Keeping Active” provides for a healthy eating style and physical activity in order to better handle diabetes. The aim of the study has been to evaluate the impact on changing eatin g habits and increasing the knowledge of the disease with the group therapeutic education through the use of C-Maps™ tool.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research
Authors: Kumar S, Gupta A, Sameja P, Patel I, Gupta S Abstract Diabetes mellitus a disease with various macro and micro vascular complications due to its various metabolic dysregulations, is well known to involve lungs in long run in both type 1 and 2 diabetes mellitus, causing tremendous burden on health care system. Common simple lung function tests alone are likely to underestimate the prevalence and degree of lung dysfunction in diabetes, but newer noninvasive tests of lung mechanical function provide a more sensitive assessment of peripheral airway function, hence by establishing a marker and risk factors for ...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Authors: Panikar V, Joshi SR, Deogaonkar N, Vadgama J, Nasikkar N, Kamat T, Sheikh S, Jain CC, Wagle T Abstract Aim: To evaluate the efficacy of SGLT2 inhibitors as an add-on therapy along with stricter lifestyle modification in Asian Indian type 2 diabetes mellitus (T2DM) patients with inadequate glycemic control despite receiving an optimum dose of at least 4 oral antidiabetic drugs (OADs). Methodology: A retrospective analysis of data of 808 T2DM patients being treated with an SGLT2 inhibitor (Dapagliflozin, Empagliflozin or Canagliflozin) as an add-on drug in patients with inadequate glycemic control despit...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
The first cardiovascular (CV) safety trial conducted with a sodium-glucose cotransporter (SGLT)-2 inhibitor, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients —Removing Excess Glucose (EMPA-REG OUTCOME), reported not only remarkable risk reductions in CV outcome, but also impressive improvements in renal outcome. Changes in renal hemodynamics could be involved in the benefit of SGLT2 inhibitors on renal outcomes. Considering that all patients of EMPA-RE G OUTCOME had established atherosclerotic CV disease at baseline, many patients were also treated with several CV drugs at baselin...
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Commentary Source Type: research
In this study, the microstructural integrity of white matter (WM) was evaluated in three groups of middle-aged subjects: healthy controls (HCs) and T2DM patients with and without peripheral microvascular complications (T2DM-C and T2DM-NC patients, respectively).MethodsDiffusion tensor imaging (DTI) and related clinical examinations were performed in 66 subjects, including 20 T2DM-C patients, 20 T2DM-NC patients, 26 age- and sex-matched HCs. Magnetic resonance imaging (MRI) at 3 T was used to perform DTI; then, FSL and tract-based spatial statistics (TBSS) software were used to assess differences in the fractional anisotr...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
Condition:   Elastic Band Resistance Exercise With Comorbid Type 2 Diabetes Mellitus and Knee Osteoarthritis Interventions:   Other: Elastic Band Resistance Exercise;   Other: active joint range-of-motion exercises and isometric contraction exercises Sponsor:   Shu-Mei Chen Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Diabetes Mellitus, Type 2 Intervention:   Drug: Diabetes mellitus Type 2 De-escalation treatment (DET) Sponsors:   Sciema UG;   Innovative Diabetes Treatment Studies LLC. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Lipidology